Mauna Kea Technologies マネジメント

マネジメント基準チェック /34

Mauna Kea Technologiesの CEO はSacha Loiseauで、 Jan2000年に任命され、の在任期間は 24.83年です。は、会社の株式の0.91%を直接所有しており、その価値は€ 102.56K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と6.8年です。

主要情報

Sacha Loiseau

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	24.8yrs
CEOの所有権	0.9%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Mauna Kea Technologies の収益と比較して、Sacha Loiseau の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€11m
Mar 31 2024	n/a	n/a	-€7m
Dec 31 2023	n/a	n/a	-€4m
Sep 30 2023	n/a	n/a	-€3m
Jun 30 2023	n/a	n/a	-€2m
Mar 31 2023	n/a	n/a	-€7m
Dec 31 2022	€173k	€84k	-€11m
Sep 30 2022	n/a	n/a	-€12m
Jun 30 2022	n/a	n/a	-€13m
Mar 31 2022	n/a	n/a	-€13m
Dec 31 2021	€207k	n/a	-€13m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€13m
Mar 31 2021	n/a	n/a	-€13m
Dec 31 2020	€325k	€156k	-€13m
Sep 30 2020	n/a	n/a	-€13m
Jun 30 2020	n/a	n/a	-€14m
Mar 31 2020	n/a	n/a	-€15m
Dec 31 2019	€252k	€164k	-€15m
Sep 30 2019	n/a	n/a	-€15m
Jun 30 2019	n/a	n/a	-€14m
Mar 31 2019	n/a	n/a	-€13m
Dec 31 2018	€639k	€197k	-€13m
Sep 30 2018	n/a	n/a	-€12m
Jun 30 2018	n/a	n/a	-€11m
Mar 31 2018	n/a	n/a	-€11m
Dec 31 2017	€256k	€205k	-€10m

報酬と市場: Sachaの総報酬がGerman市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Sachaの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sacha Loiseau

24.8yrs

在職期間

€172,636

報酬

Mr. Alexandre Loiseau, also known as Sacha, Ph.D. has been Chief Executive Officer of Mauna Kea Technologies SA since October 04, 2022. He serves as Venture Partner at Elaia Partners SAS since joining from...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alexandre Loiseau	Co-Founder	24.8yrs	€172.64k	0.91% € 102.6k
Come de La Tour du Pin	Chief Financial Officer	1.4yrs	データなし	データなし
Nathalie Lecoq	Chief Operating Officer	1.8yrs	データなし	データなし
Frederic Banegas	Chief Technology Officer	3.8yrs	データなし	データなし
François Lacombe	Chief Scientific Officer	no data	データなし	データなし
Daryl Donatelli	Vice President of Global Marketing & U.S. Sales	2.8yrs	データなし	データなし

2.8yrs

平均在職期間

経験豊富な経営陣: 1MKの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Alexandre Loiseau	Co-Founder	13.5yrs	€172.64k	0.91% € 102.6k
Molly O'Neill	Independent Director	6.8yrs	€19.00k	データなし
Christopher McFadden	Independent Director	16.8yrs	€20.00k	データなし
Claire Biot	Independent Director	4.3yrs	€15.00k	データなし
Jacquelien Ten Dam	Independent Director	3.9yrs	€20.00k	データなし

6.8yrs

平均在職期間

経験豊富なボード: 1MKの取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Mauna Kea Technologies マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies Announces Board Changes

Recent updates

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

First half 2024 earnings released

Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024

Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024

New major risk - Negative shareholders equity

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

New minor risk - Financial data availability

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

New major risk - Share price stability

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

No longer forecast to breakeven

New major risk - Revenue and earnings growth

New minor risk - Share price stability

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

No longer forecast to breakeven

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

New 90-day high: €1.55

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

New 90-day low: €1.00

New 90-day high: €1.51

New 90-day low: €1.04

New 90-day low - €1.14

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /34